SGLT2 inhibition: a new era in renoprotective medicine?
- PMID: 28666776
- DOI: 10.1016/S2213-8587(17)30222-X
SGLT2 inhibition: a new era in renoprotective medicine?
Erratum in
-
Correction to Lancet Diabetes Endocrinol 2017; 5: 569-71.Lancet Diabetes Endocrinol. 2017 Aug;5(8):e5. doi: 10.1016/S2213-8587(17)30228-0. Lancet Diabetes Endocrinol. 2017. PMID: 28732666 No abstract available.
Comment on
-
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27. Lancet Diabetes Endocrinol. 2017. PMID: 28666775
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
